M. Lonergan

发表

Cell-biologic and functional analyses of five new Aquaporin-2 missense mutations that cause recessive nephrogenic diabetes insipidus.

D. Bichet, P. Deen, D. Landau, 2002, Journal of the American Society of Nephrology : JASN.

Three families with autosomal dominant nephrogenic diabetes insipidus caused by aquaporin-2 mutations in the C-terminus.

F. Marumo, D. Bichet, Y. Terada, 2001, American journal of human genetics.

Two novel aquaporin-2 mutations responsible for congenital nephrogenic diabetes insipidus in Chinese families.

D. Bichet, S. Sasaki, M. Kuwahara, 2000, The Journal of clinical endocrinology and metabolism.

Association of calnexin with wild type and mutant AVPR2 that causes nephrogenic diabetes insipidus.

I. Nabi, D. Bichet, M. Bouvier, 2001, Biochemistry.

Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.

Michel Bouvier, D. Bichet, M. Bouvier, 2005, Journal of the American Society of Nephrology : JASN.

Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus.

P. Giampietro, D. Bichet, S. Simonetti, 1994, American journal of human genetics.

Functional studies of twelve mutant V2 vasopressin receptors related to nephrogenic diabetes insipidus: molecular basis of a mild clinical phenotype.

N. Cotte, C. Antignac, G. Alonso, 1998, Journal of the American Society of Nephrology : JASN.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm.

M. Mitchell, J. Keelan, T. Sato, 2003, The Journal of clinical endocrinology and metabolism.

Molecular identification of the gene responsible for congenital nephrogenic diabetes insipidus

D. Bichet, G. Hendy, M. Birnbaumer, 1992, Nature.

Vasopressin increases urinary albumin excretion in rats and humans: involvement of V2 receptors and the renin-angiotensin system.

M. Marre, L. Bankir, D. Bichet, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.

S. Angers, D. Bichet, M. Bouvier, 2000, The Journal of clinical investigation.

Rolipram, a phosphodiesterase inhibitor, in the treatment of two male patients with congenital nephrogenic diabetes insipidus.

D. Bichet, M. Lonergan, M. Arthus, 1990, Nephron.

Changes on recovery in the concentrations of tryptophan and the biogenic amine metabolites in the cerebrospinal fluid of patients with affective illness

I. Blackburn, M. Lonergan, G. Ashcroft, 1973, Psychological Medicine.

New autosomal recessive mutations in aquaporin‐2 causing nephrogenic diabetes insipidus through deficient targeting display normal expression in Xenopus oocytes

O. Devuyst, D. Bichet, Eva Riveira-Muñoz, 2010, The Journal of physiology.

A novel mechanism in recessive nephrogenic diabetes insipidus: wild-type aquaporin-2 rescues the apical membrane expression of intracellularly retained AQP2-P262L.

D. Bichet, P. Deen, P. van der Sluijs, 2004, Human molecular genetics.

Mutations in the vasopressin V2 receptor gene in families with nephrogenic diabetes insipidus and functional expression of the Q-2 mutant.

D. Bichet, M. Birnbaumer, A. Seibold, 1994, Cellular and molecular biology.

Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.

D. Bichet, M. Arthus, M. Lonergan, 1988, The New England journal of medicine.

1-Desamino[8-D-Arginine]Vasopressin (dDAVP) Decreases Blood Pressure and Increases Pulse Rate in Normal Individuals

D. Bichet, M. Lonergan, M. Arthus, 1988, Thrombosis and Haemostasis.

Characterization of D150E and G196D aquaporin-2 mutations responsible for nephrogenic diabetes insipidus: importance of a mild phenotype.

D. Bichet, M. Arthus, M. Lonergan, 2009, American journal of physiology. Renal physiology.

Report of 33 novel AVPR2 mutations and analysis of 117 families with X-linked nephrogenic diabetes insipidus.

D. Bichet, S. Sasaki, S. Sasaki, 2000, Journal of the American Society of Nephrology : JASN.

Human platelet fraction arginine-vasopressin. Potential physiological role.

D. Bichet, M. Lonergan, M. Arthus, 1987, The Journal of clinical investigation.

Epinephrine and dDAVP administration in patients with congenital nephrogenic diabetes insipidus. Evidence for a pre-cyclic AMP V2 receptor defective mechanism.

D. Hirsch, D. Bichet, M. Arthus, 1989, Kidney international.

Aquaporin-2: new mutations responsible for autosomal-recessive nephrogenic diabetes insipidus—update and epidemiology

D. Bichet, D. Bockenhauer, M. Arthus, 2012, Clinical kidney journal.

Heteroligomerization of an Aquaporin-2 mutant with wild-type Aquaporin-2 and their misrouting to late endosomes/lysosomes explains dominant nephrogenic diabetes insipidus.

D. Bichet, P. Deen, C. van Os, 2002, Human molecular genetics.

Functional rescue of the constitutively internalized V2 vasopressin receptor mutant R137H by the pharmacological chaperone action of SR49059.

Michel Bouvier, D. Bichet, M. Bouvier, 2004, Molecular endocrinology.

X-linked nephrogenic diabetes insipidus mutations in North America and the Hopewell hypothesis.

M. Gregory, D. Bichet, G. Hendy, 1993, The Journal of clinical investigation.

The Vasopressin Antagonist Sk&F 105494 Inhibits Desmopressin-Stimulated Clotting Factor Release in Vivo

D. Bichet, L. Kinter, M. Arthus, 1993 .

Platelet vasopressin receptors in patients with congenital nephrogenic diabetes insipidus.

D. Bichet, M. Lonergan, M. Arthus, 1991, Kidney international.

X-linked nephrogenic diabetes insipidus: from the ship Hopewell to RFLP studies.

Z. Pausova, D. Bichet, G. Hendy, 1992, American journal of human genetics.

Vasopressin antagonist inhibition of clotting factor release in the rhesus monkey (Macaca mulatta).

D. Bichet, L. Kinter, M. Arthus, 1992, The Journal of pharmacology and experimental therapeutics.

Is testing with dDAVP useful in detecting carriers of the nephrogenic diabetes insipidus gene?

D. Bichet, M. Lonergan, M. Arthus, 1991, Nephron.

An aquaporin-2 water channel mutant which causes autosomal dominant nephrogenic diabetes insipidus is retained in the Golgi complex.

P. Sluijs, D. Bichet, P. Deen, 1998, The Journal of clinical investigation.